Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors

Maryana Handula; Erik de Blois; Antonia Denkova; Yann Seimbille

Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors

Maryana Handula, Erik de Blois, Antonia Denkova, Yann Seimbille

Radiology & Nuclear Medicine

Research output: Contribution to journal › Meeting Abstract › Academic › peer-review

Original language	English
Pages (from-to)	S191-S191
Number of pages	1
Journal	Nuclear Medicine and Biology
Volume	108
Publication status	Published - 2022

Cite this

@article{50dc2ab51b0e43a5b02d9eab2a76d780,

title = "Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors",

author = "Maryana Handula and {de Blois}, Erik and Antonia Denkova and Yann Seimbille",

year = "2022",

language = "English",

volume = "108",

pages = "S191--S191",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors

AU - Handula, Maryana

AU - de Blois, Erik

AU - Denkova, Antonia

AU - Seimbille, Yann

PY - 2022

Y1 - 2022

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000802721400342&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0969-8051

VL - 108

SP - S191-S191

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

ER -

Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors

Other files and links

Cite this